A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement

Soo Youn Lee, Myung-Hyun Nam, Soo Kim June, Jong Won Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient with CYP2C9*3/*4. A 73-yr-old woman with atrial fibrilation was taking warfarin. She attained a high prothrombin time international normalized ratio (INR) at the standard doses during the induction of anticoagulation and extremely low dose of warfarin (6.5 mg/week) was finally chosen to reach the target INR. Genotyping for CYP2C9 revealed that this patient had a genotype CYP2C9*3/*4. This is the first Korean compound heterozygote for CYP2C9*3 and *4. This case suggests the clinical usefulness of pharmacogenetic testing for individualized dosage adjustments of warfarin.

Original languageEnglish
Pages (from-to)557-559
Number of pages3
JournalJournal of Korean Medical Science
Volume22
Issue number3
Publication statusPublished - 2007 Jul 12
Externally publishedYes

Fingerprint

Warfarin
Genotype
International Normalized Ratio
Prothrombin Time
Heterozygote
Cytochrome P-450 CYP2C9
Pharmaceutical Preparations

Keywords

  • Cytochrome P-450 CYP2C9
  • Pharmacogenetics
  • Polymorphism
  • Prothrombin time
  • Warfarin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement. / Lee, Soo Youn; Nam, Myung-Hyun; June, Soo Kim; Kim, Jong Won.

In: Journal of Korean Medical Science, Vol. 22, No. 3, 12.07.2007, p. 557-559.

Research output: Contribution to journalArticle

@article{6a1c0af277e9433ca595812fa3820176,
title = "A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement",
abstract = "We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient with CYP2C9*3/*4. A 73-yr-old woman with atrial fibrilation was taking warfarin. She attained a high prothrombin time international normalized ratio (INR) at the standard doses during the induction of anticoagulation and extremely low dose of warfarin (6.5 mg/week) was finally chosen to reach the target INR. Genotyping for CYP2C9 revealed that this patient had a genotype CYP2C9*3/*4. This is the first Korean compound heterozygote for CYP2C9*3 and *4. This case suggests the clinical usefulness of pharmacogenetic testing for individualized dosage adjustments of warfarin.",
keywords = "Cytochrome P-450 CYP2C9, Pharmacogenetics, Polymorphism, Prothrombin time, Warfarin",
author = "Lee, {Soo Youn} and Myung-Hyun Nam and June, {Soo Kim} and Kim, {Jong Won}",
year = "2007",
month = "7",
day = "12",
language = "English",
volume = "22",
pages = "557--559",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "3",

}

TY - JOUR

T1 - A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement

AU - Lee, Soo Youn

AU - Nam, Myung-Hyun

AU - June, Soo Kim

AU - Kim, Jong Won

PY - 2007/7/12

Y1 - 2007/7/12

N2 - We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient with CYP2C9*3/*4. A 73-yr-old woman with atrial fibrilation was taking warfarin. She attained a high prothrombin time international normalized ratio (INR) at the standard doses during the induction of anticoagulation and extremely low dose of warfarin (6.5 mg/week) was finally chosen to reach the target INR. Genotyping for CYP2C9 revealed that this patient had a genotype CYP2C9*3/*4. This is the first Korean compound heterozygote for CYP2C9*3 and *4. This case suggests the clinical usefulness of pharmacogenetic testing for individualized dosage adjustments of warfarin.

AB - We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient with CYP2C9*3/*4. A 73-yr-old woman with atrial fibrilation was taking warfarin. She attained a high prothrombin time international normalized ratio (INR) at the standard doses during the induction of anticoagulation and extremely low dose of warfarin (6.5 mg/week) was finally chosen to reach the target INR. Genotyping for CYP2C9 revealed that this patient had a genotype CYP2C9*3/*4. This is the first Korean compound heterozygote for CYP2C9*3 and *4. This case suggests the clinical usefulness of pharmacogenetic testing for individualized dosage adjustments of warfarin.

KW - Cytochrome P-450 CYP2C9

KW - Pharmacogenetics

KW - Polymorphism

KW - Prothrombin time

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=34447116378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447116378&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 557

EP - 559

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 3

ER -